Fresenius Medical Care AG & Co. KGaA ADR (FMS)
Is Fresenius Medical Care AG & Co. (FMS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Fresenius (FMS) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Fresenius (FMS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
FMS Stock Gains Following Stake Sale to Reduce Debt & Boost Profit
Fresenius Medical Care's parent company sells 10.6 million shares, the proceeds of which will be used to reduce its leverage and achieve higher profits in 2025.
Should Value Investors Buy Fresenius Medical Care AG & Co. (FMS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Fresenius Medical Care's stock falls on Fresenius' stake sale
Dialysis firm Fresenius Medical Care shares fell 7.8% after German healthcare group Fresenius SE sold part of its stake in the company.
Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom
FMS, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.
Fresenius Medical Q4 Earnings Beat Estimates, Revenues Up Y/Y
FMS' fourth-quarter results showcase a strong segmental performance along with providing full year 2025 outlook for revenue growth and operating income.
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Fresenius Medical Care slightly beats market estimates in fourth quarter
Fresenius Medical Care , the world's largest dialysis specialist, reported fourth quarter results slightly above market expectations on Tuesday, citing positive development both in its care delivery and care enablement segments.
Fresenius Medical Care: A 'Buy' Going Into 2025
Fresenius Medical Care is a leader in global kidney care, showing significant growth and an 18.5% increase since my last article. The company is attractively valued, trading at less than 18.5x P/E, with a fair value estimate of at least $34/share. Risks include political factors in the US healthcare system and technological advancements, but the company's diversification and home-care model are strong positives.
Fresenius (FMS) Upgraded to Strong Buy: Here's What You Should Know
Fresenius (FMS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
